The Food and Drug Administration (FDA) has authorised Spinogenix to begin its Expanded Access Program (EAP) for SPG302 in the United States for people with amyotrophic lateral sclerosis (ALS) that meet programme eligibility criteria. SPG302 is being developed as the first synaptic regenerative approach to treating ALS, with the potential to slow or reverse declines […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!